T van Gelder

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi request reprint Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice?
    Teun van Gelder
    Department of Hospital Pharmacy, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    Drugs 64:1737-41. 2004
  2. doi request reprint Report of the second joint meeting of ESOT and AST: current pipelines in biotech and pharma
    Teun van Gelder
    Erasmus MC, Rotterdam, The Netherlands
    Transpl Int 26:938-48. 2013
  3. doi request reprint Methods, strengths, weaknesses, and limitations of bioequivalence tests with special regard to immunosuppressive drugs
    Teun van Gelder
    Department of Hospital Pharmacy and Internal Medicine, Erasmus Medical Center, CA, Rotterdam, The Netherlands
    Transpl Int 26:771-7. 2013
  4. ncbi request reprint The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation
    Teun van Gelder
    Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands
    Transplantation 80:S244-53. 2005
  5. ncbi request reprint Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil
    Teun van Gelder
    Department of Internal Medicine Nephrology, University Hospital Rotterdam, Rotterdam, The Netherlands
    Transplantation 75:788-91. 2003
  6. doi request reprint Mycophenolate blood level monitoring: recent progress
    T van Gelder
    Department of Hospital Pharmacy, Clinical Pharmacology Unit, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands
    Am J Transplant 9:1495-9. 2009
  7. doi request reprint Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method
    Teun van Gelder
    Department of Hospital Pharmacy, Erasmus Medical Center, Molewaterplein 40, Rotterdam, The Netherlands
    Ther Drug Monit 31:218-23. 2009
  8. doi request reprint Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?
    T van Gelder
    Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands
    Clin Pharmacol Ther 87:640-1. 2010
  9. doi request reprint How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation
    Teun van Gelder
    Department of Hospital Pharmacy and Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Ther Drug Monit 33:155-64. 2011
  10. doi request reprint Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial
    Teun van Gelder
    1Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands
    Transplantation 86:1043-51. 2008

Collaborators

Detail Information

Publications45

  1. ncbi request reprint Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice?
    Teun van Gelder
    Department of Hospital Pharmacy, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    Drugs 64:1737-41. 2004
    ..With both compounds, a significant reduction in the number of acute rejection episodes following solid organ transplantation can be obtained without an increase in adverse effects or infectious complications...
  2. doi request reprint Report of the second joint meeting of ESOT and AST: current pipelines in biotech and pharma
    Teun van Gelder
    Erasmus MC, Rotterdam, The Netherlands
    Transpl Int 26:938-48. 2013
    ..Thus, the topic of this second meeting "Transformational therapies and diagnostics in transplantation" was devised and a summary of this meeting follows. ..
  3. doi request reprint Methods, strengths, weaknesses, and limitations of bioequivalence tests with special regard to immunosuppressive drugs
    Teun van Gelder
    Department of Hospital Pharmacy and Internal Medicine, Erasmus Medical Center, CA, Rotterdam, The Netherlands
    Transpl Int 26:771-7. 2013
    ..This article describes the registration requirements with a focus on bioequivalence testing, the strengths and weaknesses in this process, and the differences between Europe and the US. ..
  4. ncbi request reprint The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation
    Teun van Gelder
    Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands
    Transplantation 80:S244-53. 2005
    ....
  5. ncbi request reprint Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil
    Teun van Gelder
    Department of Internal Medicine Nephrology, University Hospital Rotterdam, Rotterdam, The Netherlands
    Transplantation 75:788-91. 2003
    ..In an attempt to reduce calcineurin inhibitor toxicity, transplant patients treated with tacrolimus can be switched to maintenance treatment with sirolimus...
  6. doi request reprint Mycophenolate blood level monitoring: recent progress
    T van Gelder
    Department of Hospital Pharmacy, Clinical Pharmacology Unit, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands
    Am J Transplant 9:1495-9. 2009
    ....
  7. doi request reprint Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method
    Teun van Gelder
    Department of Hospital Pharmacy, Erasmus Medical Center, Molewaterplein 40, Rotterdam, The Netherlands
    Ther Drug Monit 31:218-23. 2009
    ..9 mg/L with BPAR and 1.7 mg/L without BPAR). The Roche Total MPA assay is a reliable alternative to LC-MS/MS. It can be applied in the clinical setting allowing for easy, fast, and optimized patient management...
  8. doi request reprint Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?
    T van Gelder
    Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands
    Clin Pharmacol Ther 87:640-1. 2010
    ..2) Typically, predose concentrations are monitored and the dose is adjusted to aim for target values that depend on immunological risk, comedication, and time since transplantation.(2)...
  9. doi request reprint How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation
    Teun van Gelder
    Department of Hospital Pharmacy and Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Ther Drug Monit 33:155-64. 2011
    ..Patients with delayed graft function (DGF) after renal transplantation are exposed to low total MPA concentrations, when risk of rejection is highest. This study investigated the influence of DGF on MPA exposure and on clinical outcome...
  10. doi request reprint Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial
    Teun van Gelder
    1Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands
    Transplantation 86:1043-51. 2008
    ..The Fixed-Dose Concentration Controlled trial assessed the feasibility and potential benefit of therapeutic drug monitoring in patients receiving MMF after de novo renal transplant...
  11. ncbi request reprint Pharmacogenetics in immunosuppressive therapy: the best thing since TDM?
    Teun van Gelder
    Department of Hospital Pharmacy, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands
    Ther Drug Monit 26:343-6. 2004
  12. ncbi request reprint Therapeutic drug monitoring of mycophenolate mofetil in transplantation
    Teun van Gelder
    Department of Hospital Pharmacy, Clinical Pharmacology Unit, Erasmus Medical Center, Rotterdam, The Netherlands
    Ther Drug Monit 28:145-54. 2006
    ..The value of TDM in the general transplant population will be assessed from large, ongoing, randomized studies...
  13. ncbi request reprint [Kidney transplantation: more kidneys from living donors, individualised immunosuppression and better results]
    T van Gelder
    afd Inwendige Geneeskunde, Erasmus Medisch Centrum, Postbus 2040, 3000 CA Rotterdam
    Ned Tijdschr Geneeskd 147:955-9. 2003
    ..This is complicated by acute rejection episodes in 10-20% of patients. With the arrival of a number of new immunosuppressive drugs the risk of rejection might be reduced...
  14. ncbi request reprint Anti-CD25 monoclonal antibody therapy affects the death signals of graft-infiltrating cells after clinical heart transplantation
    C C Baan
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Transplantation 75:1704-10. 2003
    ....
  15. doi request reprint The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients
    P W Schenk
    Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
    Pharmacogenomics J 10:219-25. 2010
    ....
  16. ncbi request reprint The nature of acute rejection is associated with development of graft vascular disease after clinical heart transplantation
    C C Baan
    Department of Internal Medicine 1, University Hospital Rotterdam Dijkzigt, Rotterdam, The Netherlands
    J Heart Lung Transplant 17:363-73. 1998
    ..To determine mechanisms that trigger graft vascular disease (GVD) after heart transplantation, we studied parameters that reflect both early and late intragraft allogeneic reactions...
  17. ncbi request reprint Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients
    P J Gregoor
    Department of Internal Medicine I, University Hospital Rotterdam, The Netherlands
    Transplantation 68:1603-6. 1999
    ..Several drug interactions with MMF are known. We investigated the influence of CsA withdrawal on MPA trough levels in renal transplant patients...
  18. ncbi request reprint IL-15R alpha-chain expression during anti-CD25 treatment of cardiac allograft recipients
    C C Baan
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Transplant Proc 34:3243-5. 2002
  19. ncbi request reprint A longitudinal study of TGF-beta1 protein levels in renal allograft recipients converted from CsA to MMF or AZA
    B J van der Mast
    Department of Internal Medicine I, University Hospital Rotterdam Dijkzigt, Rotterdam, The Netherlands
    Clin Transplant 14:66-9. 2000
    ..In conclusion, we did not observe higher TGF-beta1 plasma levels in plasma levels of patients receiving CsA treatment compared to blood from the same patients while on AZA or MMF...
  20. ncbi request reprint The relative importance of cyclosporine exposure in heart, kidney or liver transplant recipients on maintenance therapy
    D A Hesselink
    Department of Internal Medicine, Renal Transplant Unit, Erasmus Medical Center, Dr Molewaterplein 50, 3015 DR, Rotterdam, The Netherlands
    Transpl Int 17:495-504. 2004
    ....
  21. ncbi request reprint Mycophenolic acid trough levels after kidney transplantation in a cyclosporine-free protocol
    P J Smak Gregoor
    Department of Internal Medicine I, University Hospital Rotterdam, The Netherlands
    Transpl Int 13:S333-5. 2000
    ..8 microg/ml (1.48-6.52) in patients without an acute rejection (P = 0.25). We conclude that there is a significant relation between MPA trough levels and MMF dose. MPA trough levels were not predictive of rejection in the present study...
  22. doi request reprint UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients
    R H N Van Schaik
    Department of Clinical Chemistry, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Clin Pharmacol Ther 86:319-27. 2009
    ..3, 95% confidence interval 1.1-162.3; P < 0.05). UGT1A9 -275T>A and/or -2152C>T genotyping may identify patients at risk of MPA underexposure and acute rejection when receiving treatment with MMF and tacrolimus...
  23. doi request reprint Effects of CYP induction by rifampicin on tamoxifen exposure
    L Binkhorst
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The Netherlands
    Clin Pharmacol Ther 92:62-7. 2012
    ..Given the extensive metabolism undergone by tamoxifen, several factors may have contributed to this effect. Similar drug-drug interactions may exist between tamoxifen and other strong CYP inducers...
  24. ncbi request reprint Evaluation of the new EMIT enzyme immunoassay for the determination of whole-blood tacrolimus concentrations in kidney, heart, and liver transplant recipients
    C J Hesse
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Transplant Proc 34:2988-90. 2002
  25. doi request reprint Practicability of pharmacogenetics in transplantation medicine
    T van Gelder
    1 Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands 2 Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Clin Pharmacol Ther 95:262-4. 2014
    ..The contribution of genotype-based dosing will be more pronounced for drugs for which pharmacokinetic or pharmacodynamic monitoring is not applied. ..
  26. doi request reprint Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(†)
    R Bouamar
    Department of Hospital Pharmacy, Erasmus MC, Rotterdam, The Netherlands
    Am J Transplant 13:1253-61. 2013
    ..Based on this study it is not possible to define the optimal target concentrations for Tac...
  27. ncbi request reprint High mycophenolic acid area under-the-curve values in renal transplant recipients on long-term mycophenolate mofetil treatment
    R Engelbertink
    Department of Internal Medicine, University Hospital Rotterdam, The Netherlands
    Transplant Proc 34:2983-4. 2002
  28. ncbi request reprint [Twenty-five years of cyclosporin use in transplantation medicine]
    D A Hesselink
    afd Inwendige Geneeskunde, sectie Transplantatie, Erasmus Medisch Centrum, Dr Molewaterplein 50, 3015 GE Rotterdam
    Ned Tijdschr Geneeskd 147:959-64. 2003
    ..Finally, the introduction of new immunosuppressive drugs has made it possible to further reduce the dose of cyclosporin; this might eventually lead to cyclosporin-free immunosuppressive regimens...
  29. pmc The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer
    L A Lammers
    Department of Hospital Pharmacy, Erasmus MC, University Hospital, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
    Br J Cancer 103:765-71. 2010
    ....
  30. ncbi request reprint Ischemia times and donor serum creatinine in relation to renal graft failure
    J I Roodnat
    Department of Internal Medicine, University Hospital Rotterdam Dijkzigt, Rotterdam, The Netherlands
    Transplantation 75:799-804. 2003
    ..The results of renal transplantation are dependent on many variables. To simplify the decision process related to a kidney offer, the authors wondered which variables had the most important influence on the graft failure risk...
  31. doi request reprint Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users
    M J Bijl
    Department of Epidemiology and Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands
    Clin Pharmacol Ther 85:45-50. 2009
    ..0014). The diastolic blood pressure in PMs was 5.4 mm Hg lower in users of beta-blockers metabolized by CYP2D6 (P = 0.017) and 4.8 mm Hg lower in metoprolol users (P = 0.045) compared with EMs. PMs are at increased risk of bradycardia...
  32. ncbi request reprint Unusual presentation of herpes virus infections in renal transplant recipients exposed to high mycophenolic acid plasma concentrations
    P J H Smak Gregoor
    Department of Internal Medicine, Room D 412, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Transpl Infect Dis 5:79-83. 2003
    ..High MPA levels may reflect over-immunosuppression resulting in infectious complications...
  33. ncbi request reprint Anti-CD25 therapy impairs donor-specific Th1 and Th2 cytokine-producing peripheral blood cells after clinical heart transplantation
    N M van Besouw
    Department of Internal Medicine, University Hospital Rotterdam Dijkzigt, Rotterdam, The Netherlands
    Transplant Proc 34:2942-3. 2002
  34. ncbi request reprint C-reactive protein in the monitoring of acute rejection after heart transplantation
    T van Gelder
    Department of Internal Medicine I, University Hospital Rotterdam, The Netherlands
    Transpl Int 11:361-4. 1998
    ..We did, however, find a prognostic significance with regard to the effect of rejection treatment: in all acute rejections with a CRP < or = 3 (n = 11), steroids were effective...
  35. doi request reprint Individualization of tamoxifen treatment for breast carcinoma
    L Binkhorst
    Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Clin Pharmacol Ther 92:431-3. 2012
    ..Phenotyping approaches, as well as therapeutic drug monitoring (TDM) strategies, are now being tested to individualize tamoxifen treatment...
  36. ncbi request reprint Atypical mycobacterium infection with dermatological manifestation in a renal transplant recipient
    J J de Jong
    Department of Internal Medicine and Nephrology, Ikazia Hospital, Rotterdam, The Netherlands
    Transpl Int 12:71-3. 1999
    ..The combination of relatively minor symptoms with enlarged purulent lesions, causing severe morbidity, raises the possibility of NTM infection in the immunocompromised patient...
  37. ncbi request reprint Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients
    P W Schenk
    Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands
    Mol Psychiatry 13:597-605. 2008
    ..Therefore, therapeutic efficacy and efficiency may be improved, the number of adverse drug reactions decreased, and hospital stay reduced...
  38. doi request reprint Renal function as a predictor of irinotecan-induced neutropenia
    F A De Jong
    Department of Medical Oncology, Erasmus University Medical Center Rotterdam Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Clin Pharmacol Ther 84:254-62. 2008
    ..A confirmatory analysis is warranted to determine whether measures of renal function should be incorporated in future attempts toward individualized treatment with irinotecan...
  39. ncbi request reprint The superior results of living-donor renal transplantation are not completely caused by selection or short cold ischemia time: a single-center, multivariate analysis
    J I Roodnat
    Department of Internal Medicine, University Hospital Rotterdam Dijkzigt, The Netherlands
    Transplantation 75:2014-8. 2003
    ..To investigate whether this can be explained by a more favorable patient selection procedure in the LD population, we performed a Cox proportional hazards analysis including variables with a known influence on graft survival...
  40. ncbi request reprint The Cox proportional hazards analysis in words: examples in the renal transplantation field
    J I Roodnat
    Department of Internal Medicine, University Hospital, Rotterdam Dijkzigt, The Netherlands
    Transplantation 77:483-8. 2004
    ..In a complex, observational study concerning a multifactor-influenced population such as the renal transplant population, the use of the Cox model is mandatory to unravel the influences of the different variables on the failure rate...
  41. ncbi request reprint Mycophenolate mofetil and post-transplant glomerular disease
    T van Gelder
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Nephron Clin Pract 98:c59-60. 2004
  42. ncbi request reprint Successful vaccination against varicella zoster virus prior to kidney transplantation
    A Geel
    Department of Internal Medicine, Section Transplantation, Rotterdam, The Netherlands
    Transplant Proc 37:952-3. 2005
    ..We questioned how many patients on the waiting list for kidney transplantation had not been protected against VZV and whether patients with renal insufficiency would be able to develop a specific immune response upon VZV vaccination...
  43. ncbi request reprint A clinical approach to pharmacogenetics
    L C G de Graaff
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Neth J Med 71:145-52. 2013
    ..We discuss the availability and costs of pharmacogenetic testing, show a calculation of the 'number needed to genotype' and, based on these data, we propose a decision model for pharmacogenetic testing by clinicians...
  44. ncbi request reprint [Fatal fibrosing cholestatic hepatitis following renal transplantation]
    D Sprengers
    afd Maag, Darm en Leverziekten, Erasmus Medisch Centrum, Postbus 2040, 3000 CA Rotterdam
    Ned Tijdschr Geneeskd 146:1380-4. 2002
    ..This case illustrates the importance of early diagnosis and treatment with reduction of immunosuppression and institution of antiviral therapy to prevent progression of FCH in immunocompromised HBsAg positive patients...
  45. pmc Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring
    Brenda C M de Winter
    Department of Hospital Pharmacy, Clinical Pharmacology Unit, Rotterdam, The Netherlands
    Clin J Am Soc Nephrol 6:656-63. 2011
    ..When MMF doses are adjusted, a linear relationship between dose and MPA exposure is assumed. In this study, the linearity of MMF pharmacokinetics was investigated...